Is there a place for mesenchymal stromal cell-based therapies in the therapeutic armamentarium against COVID-19?

Stem Cell Research & Therapy

Fernanda de Macêdo Lima¹  André Luiz Nunes Gobatto¹  Zaquer Suzana Munhoz Costa-Ferro²  Luciana Souza de Aragão França²  Carolina Kymie Vasques Nonaka²  Bruno Raphael Ribeiro Cavalcante³  Bruno Solano de Freitas Souza⁴  Kátia Nunes da Silva⁴  Alex Cleber Improta Caria⁵  Miquéias Lopes-Pacheco⁶  Patricia Rieken Macêdo Rocco⁷ 

[1] Center for Biotechnology and Cell Therapy, São Rafael Hospital, Salvador, Brazil;D’Or Institute for Research and Education (IDOR), Salvador, Brazil;Center for Biotechnology and Cell Therapy, São Rafael Hospital, Salvador, Brazil;Goncalo Moniz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Rua Waldemar Falcão, 121, Candeal, 40296-710, Salvador, Bahia, Brazil;Goncalo Moniz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Rua Waldemar Falcão, 121, Candeal, 40296-710, Salvador, Bahia, Brazil;D’Or Institute for Research and Education (IDOR), Salvador, Brazil;Center for Biotechnology and Cell Therapy, São Rafael Hospital, Salvador, Brazil;Graduate Program in Medicine and Health, Faculty of Medicine, Federal University of Bahia, Salvador, Brazil;Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil;Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil;National Institute of Science and Technology for Regenerative Medicine, Rio de Janeiro, Rio de Janeiro, Brazil;COVID-19 Virus Network, Ministry of Science and Technology, and Innovation, Rio de Janeiro, Brazil;

关键词: COVID-19;    Cell therapy;    Mesenchymal stromal cells;    Acute respiratory distress syndrome;    SARS-CoV-2;   

DOI  :  10.1186/s13287-021-02502-7

来源: Springer

【 摘 要 】

The COVID-19 pandemic, caused by the rapid global spread of the novel coronavirus (SARS-CoV-2), has caused healthcare systems to collapse and led to hundreds of thousands of deaths. The clinical spectrum of COVID-19 is not only limited to local pneumonia but also represents multiple organ involvement, with potential for systemic complications. One year after the pandemic, pathophysiological knowledge has evolved, and many therapeutic advances have occurred, but mortality rates are still elevated in severe/critical COVID-19 cases. Mesenchymal stromal cells (MSCs) can exert immunomodulatory, antiviral, and pro-regenerative paracrine/endocrine actions and are therefore promising candidates for MSC-based therapies. In this review, we discuss the rationale for MSC-based therapies based on currently available preclinical and clinical evidence of safety, potential efficacy, and mechanisms of action. Finally, we present a critical analysis of the risks, limitations, challenges, and opportunities that place MSC-based products as a therapeutic strategy that may complement the current arsenal against COVID-19 and reduce the pandemic’s unmet medical needs.

【 授权许可】

CC BY